BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24603710)

  • 21. The prognosis and survival analysis according to seven staging systems of hepatocellular carcinoma following curative resection.
    Choi SB; Lee JG; Kim KS; Yoon DS; Choi JS; Lee WJ; Kim BR
    Hepatogastroenterology; 2008; 55(88):2140-5. PubMed ID: 19260493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.
    Marrero JA; Fontana RJ; Barrat A; Askari F; Conjeevaram HS; Su GL; Lok AS
    Hepatology; 2005 Apr; 41(4):707-16. PubMed ID: 15795889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems.
    Shao YY; Lu LC; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Br J Cancer; 2012 Nov; 107(10):1672-7. PubMed ID: 23059748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposal of the performance status combined Japan Integrated Staging system in hepatocellular carcinoma complicated with cirrhosis.
    Nishikawa H; Kita R; Kimura T; Endo M; Ohara Y; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Osaki Y
    Int J Oncol; 2015; 46(6):2371-9. PubMed ID: 25891119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population.
    Urakawa H; Kora SI; Mitsufuji T; Osame A; Higahsihara H; Yoshimitsu K
    Acta Radiol; 2016 Dec; 57(12):1445-1452. PubMed ID: 26861204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.
    Chen CH; Hu FC; Huang GT; Lee PH; Tsang YM; Cheng AL; Chen DS; Wang JD; Sheu JC
    Eur J Cancer; 2009 Jun; 45(9):1630-9. PubMed ID: 19157858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.
    Chan SL; Mo FK; Johnson PJ; Liem GS; Chan TC; Poon MC; Ma BB; Leung TW; Lai PB; Chan AT; Mok TS; Yeo W
    J Gastroenterol Hepatol; 2011 Feb; 26(2):340-7. PubMed ID: 21261725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy.
    Nanashima A; Sumida Y; Abo T; Shindou H; Fukuoka H; Takeshita H; Hidaka S; Tanaka K; Sawai T; Yasutake T; Nagayasu T; Omagari K; Mine M
    J Gastroenterol; 2006 Mar; 41(3):250-6. PubMed ID: 16699859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.
    Lee JH; Kim HY; Kim YJ; Yoon JH; Chung JW; Lee HS
    J Gastroenterol Hepatol; 2015 Apr; 30(4):696-705. PubMed ID: 25250761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
    Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
    World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of predictive value of Okuda, TNM, CLIP and JIS staging systems for hepatocellular carcinoma patients].
    Lee SW; Han SY; Kim KT; Baek YH; Koh IY; Kim BH; Park EH; Jang JS; Roh MH; Choi JC
    Korean J Hepatol; 2007 Jun; 13(2):196-207. PubMed ID: 17585193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
    Am J Gastroenterol; 2005 Aug; 100(8):1764-71. PubMed ID: 16086713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy.
    Seong J; Shim SJ; Lee IJ; Han KH; Chon CY; Ahn SH
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1037-42. PubMed ID: 17234356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems.
    Cammà C; Di Marco V; Cabibbo G; Latteri F; Sandonato L; Parisi P; Enea M; Attanasio M; Galia M; Alessi N; Licata A; Latteri MA; Craxì A
    Aliment Pharmacol Ther; 2008 Jul; 28(1):62-75. PubMed ID: 18373636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma.
    Rabe C; Lenz M; Schmitz V; Pilz T; Fimmers R; Sauerbruch T; Caselmann WH
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1305-15. PubMed ID: 14624154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
    Yegin EG; Siykhymbayev A; Eren F; Bekiroglu N; Ozdogan OC
    Ann Hepatol; 2013; 12(6):915-25. PubMed ID: 24114822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic factors for survival in patients with hepatocellular carcinoma after radiofrequency ablation].
    Lee JH; Han SY; Jo JH; Kim SK; Go BS; Oh JY; Choi JC; Lee SW; Jang JS; Roh MH
    Korean J Gastroenterol; 2007 Jan; 49(1):17-23. PubMed ID: 18167429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.
    Collette S; Bonnetain F; Paoletti X; Doffoel M; Bouché O; Raoul JL; Rougier P; Masskouri F; Bedenne L; Barbare JC
    Ann Oncol; 2008 Jun; 19(6):1117-26. PubMed ID: 18303031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.